<?xml version="1.0" encoding="UTF-8"?>
<p id="p0245">Regarding SARS-CoV-2 results, 
 <italic>in-silico</italic> evaluation of SBV indicated the existence of a strong bond to SARS-CoV-RdRp, which confirms the mechanism of this molecule against other viruses and reinforces its potential against COVID-19.
 <xref rid="b0035" ref-type="bibr">
  <sup>7</sup>
 </xref> This was confirmed by another 
 <italic>in-silico</italic> investigation that suggested repurposing of sofosbuvir/velpatasvir (Epclusa) or sofosbuvir/ledipasvir (Harvoni). Such indication is grounded on the fact that these drugs induce two coronaviruses enzymes and reduce risks of resistance.
</p>
